The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Gatiquin     1-cyclopropyl-6-fluoro-8- methoxy-7-(3...

Synonyms: Gatispan, Gatiflo, Gatilox, Zymaxid, Tequin, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Gatiflo


Psychiatry related information on Gatiflo


High impact information on Gatiflo


Chemical compound and disease context of Gatiflo


Biological context of Gatiflo


Anatomical context of Gatiflo


Associations of Gatiflo with other chemical compounds


Gene context of Gatiflo


Analytical, diagnostic and therapeutic context of Gatiflo


  1. Pharmacodynamic profiling of levofloxacin and gatifloxacin using Monte Carlo simulation for community-acquired isolates of Streptococcus pneumoniae. Nicolau, D.P., Ambrose, P.G. Am. J. Med. (2001) [Pubmed]
  2. Severe and persistent hypoglycemia due to gatifloxacin interaction with oral hypoglycemic agents. Menzies, D.J., Dorsainvil, P.A., Cunha, B.A., Johnson, D.H. Am. J. Med. (2002) [Pubmed]
  3. Frequency of pathogen occurrence and antimicrobial susceptibility among community-acquired respiratory tract infections in the respiratory surveillance program study: microbiology from the medical office practice environment. Pfaller, M.A., Ehrhardt, A.F., Jones, R.N. Am. J. Med. (2001) [Pubmed]
  4. Myoclonus and generalized seizures associated with gatifloxacin treatment. Marinella, M.A. Arch. Intern. Med. (2001) [Pubmed]
  5. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Wakabayashi, E., Mitsuhashi, S. Antimicrob. Agents Chemother. (1994) [Pubmed]
  6. Gatifloxacin-induced hallucinations in a 19-year-old man. Adams, M., Tavakoli, H. Psychosomatics. (2006) [Pubmed]
  7. Gatifloxacin interference with opiate urine drug screen. Straley, C.M., Cecil, E.J., Herriman, M.P. Pharmacotherapy (2006) [Pubmed]
  8. Single-dose fluoroquinolone therapy of acute uncomplicated urinary tract infection in women: results from a randomized, double-blind, multicenter trial comparing single-dose to 3-day fluoroquinolone regimens. Richard, G.A., Mathew, C.P., Kirstein, J.M., Orchard, D., Yang, J.Y. Urology (2002) [Pubmed]
  9. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Segreti, J., House, H.R., Siegel, R.E. Am. J. Med. (2005) [Pubmed]
  10. Rational antibiotic treatment of outpatient genitourinary infections in a changing environment. David, R.D., DeBlieux, P.M., Press, R. Am. J. Med. (2005) [Pubmed]
  11. The expanding role of fluoroquinolones. Schaeffer, A.J. Am. J. Med. (2002) [Pubmed]
  12. Interactions of a series of fluoroquinolone antibacterial drugs with the human cardiac K+ channel HERG. Kang, J., Wang, L., Chen, X.L., Triggle, D.J., Rampe, D. Mol. Pharmacol. (2001) [Pubmed]
  13. Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease? Dhalla, I.A., Mamdani, M.M., Simor, A.E., Kopp, A., Rochon, P.A., Juurlink, D.N. Antimicrob. Agents Chemother. (2006) [Pubmed]
  14. In vitro and in vivo antibacterial activities of AM-1155, a new 6-fluoro-8-methoxy quinolone. Hosaka, M., Yasue, T., Fukuda, H., Tomizawa, H., Aoyama, H., Hirai, K. Antimicrob. Agents Chemother. (1992) [Pubmed]
  15. Fluoroquinolone Resistance in Streptococcus pneumoniae: Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin. Laplante, K.L., Rybak, M.J., Tsuji, B., Lodise, T.P., Kaatz, G.W. Antimicrob. Agents Chemother. (2007) [Pubmed]
  16. A critical review of the fluoroquinolones: focus on respiratory infections. Zhanel, G.G., Ennis, K., Vercaigne, L., Walkty, A., Gin, A.S., Embil, J., Smith, H., Hoban, D.J. Drugs (2002) [Pubmed]
  17. In Vitro Susceptibility of Clostridium difficile Clinical Isolates from a Multi-Institutional Outbreak in Southern Quebec, Canada. Bourgault, A.M., Lamothe, F., Loo, V.G., Poirier, L. Antimicrob. Agents Chemother. (2006) [Pubmed]
  18. Population pharmacokinetic model for gatifloxacin in pediatric patients. Rubino, C.M., Capparelli, E.V., Bradley, J.S., Blumer, J.L., Kearns, G.L., Reed, M., Jacobs, R.F., Cirincione, B., Grasela, D.M. Antimicrob. Agents Chemother. (2007) [Pubmed]
  19. Gatifloxacin: a review of its use in the management of bacterial infections. Perry, C.M., Ormrod, D., Hurst, M., Onrust, S.V. Drugs (2002) [Pubmed]
  20. Comparative pharmacodynamics of gatifloxacin and ciprofloxacin in an in vitro dynamic model: prediction of equiefficient doses and the breakpoints of the area under the curve/MIC ratio. Vostrov, S.N., Kononenko, O.V., Lubenko, I.Y., Zinner, S.H., Firsov, A.A. Antimicrob. Agents Chemother. (2000) [Pubmed]
  21. Pharmacodynamic profile of telithromycin against macrolide- and fluoroquinolone-resistant Streptococcus pneumoniae in a neutropenic mouse thigh model. Tessier, P.R., Mattoes, H.M., Dandekar, P.K., Nightingale, C.H., Nicolau, D.P. Antimicrob. Agents Chemother. (2005) [Pubmed]
  22. Uptake and intracellular activity of AM-1155 in phagocytic cells. Yamamoto, T., Kusajima, H., Hosaka, M., Fukuda, H., Oomori, Y., Shinoda, H. Antimicrob. Agents Chemother. (1996) [Pubmed]
  23. The 6-Fluoro-8-Methoxy Quinolone Gatifloxacin Down-Regulates Interleukin-8 Production in Prostate Cell Line PC-3. Takeyama, K., Mitsuzawa, H., Nishitani, C., Shimizu, T., Sano, H., Kunishima, Y., Takahashi, S., Hotta, H., Matsukawa, M., Shibata, K., Tsukamoto, T., Kuroki, Y. Antimicrob. Agents Chemother. (2007) [Pubmed]
  24. Efficacy of gatifloxacin in experimental Escherichia coli meningitis. Lutsar, I., Friedland, I.R., Jafri, H.S., Wubbel, L., Ng, W., Ghaffar, F., McCracken, G.H. Antimicrob. Agents Chemother. (1999) [Pubmed]
  25. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases. Takei, M., Fukuda, H., Yasue, T., Hosaka, M., Oomori, Y. Antimicrob. Agents Chemother. (1998) [Pubmed]
  26. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents. Kosowska-Shick, K., Credito, K., Pankuch, G.A., Lin, G., Bozdogan, B., McGhee, P., Dewasse, B., Choi, D.R., Ryu, J.M., Appelbaum, P.C. Antimicrob. Agents Chemother. (2006) [Pubmed]
  27. Primary targets of fluoroquinolones in Streptococcus pneumoniae. Fukuda, H., Hiramatsu, K. Antimicrob. Agents Chemother. (1999) [Pubmed]
  28. Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care. Dean, N.C., Sperry, P., Wikler, M., Suchyta, M.S., Hadlock, C. Antimicrob. Agents Chemother. (2006) [Pubmed]
  29. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnesium. Lober, S., Ziege, S., Rau, M., Schreiber, G., Mignot, A., Koeppe, P., Lode, H. Antimicrob. Agents Chemother. (1999) [Pubmed]
  30. In vitro activities of new quinolones and oxazolidinones against Actinomadura madurae. Vera-Cabrera, L., Ochoa-Felix, E.Y., Gonzalez, G., Tijerina, R., Choi, S.H., Welsh, O. Antimicrob. Agents Chemother. (2004) [Pubmed]
  31. Effects of fluoroquinolones on the migration of human phagocytes through Chlamydia pneumoniae-infected and tumor necrosis factor alpha-stimulated endothelial cells. Uriarte, S.M., Molestina, R.E., Miller, R.D., Bernabo, J., Farinati, A., Eiguchi, K., Ramirez, J.A., Summersgill, J.T. Antimicrob. Agents Chemother. (2004) [Pubmed]
  32. Selection of a gyrA Mutation and Treatment Failure with Gatifloxacin in a Patient with Streptococcus pneumoniae with a Preexisting parC Mutation. Kays, M.B., Zhanel, G.G., Reimann, M.A., Jacobi, J., Denys, G.A., Smith, D.W., Wack, M.F. Pharmacotherapy (2007) [Pubmed]
  33. Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus. Bosso, J.A., Mauldin, P.D. Antimicrob. Agents Chemother. (2006) [Pubmed]
  34. Open-label, nonrandomized study of the effects of gatifloxacin on the pharmacokinetics of midazolam in healthy male volunteers. Grasela, D.M., LaCreta, F.P., Kollia, G.D., Randall, D.M., Uderman, H.D. Pharmacotherapy (2000) [Pubmed]
  35. Epidemiology of sinusitis in the primary care setting: results from the 1999-2000 respiratory surveillance program. Sokol, W. Am. J. Med. (2001) [Pubmed]
  36. Concentrations of gatifloxacin in plasma and urine and penetration into prostatic and seminal fluid, ejaculate, and sperm cells after single oral administrations of 400 milligrams to volunteers. Naber, C.K., Steghafner, M., Kinzig-Schippers, M., Sauber, C., Sörgel, F., Stahlberg, H.J., Naber, K.G. Antimicrob. Agents Chemother. (2001) [Pubmed]
  37. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Tarshis, G.A., Miskin, B.M., Jones, T.M., Champlin, J., Wingert, K.J., Breen, J.D., Brown, M.J. Antimicrob. Agents Chemother. (2001) [Pubmed]
WikiGenes - Universities